Funny But Yet Motivational Quotes On Forskolin

Two previous reports have evaluated the impact of comorbidities on outcome in older patients undergoing ASCT. Wildes et al. [2] compared 59 patients aged 60 and older to younger patients, showing no difference overall in DFS or OS, but a significant impact of CCI on TRM and OS. Hosing et al. [3] found that, in patients over age 65 undergoing ASCT, HCT-CI predicted for increased toxicity during transplant, but had no impact on OS. Andorsky et al. recently published the first data of which we are aware evaluating ASCT in lymphoma patients 70 years of age and older [11]. In this small group of 17 patients, 1-year nonrelapse mortality was 35%. CCI and HCT-CI were calculated but were not predictive for survival in this group. No pretransplant characteristics were identified http://www.selleck.cn/products/AZD0530.html that could help identify patients who would be at prohibitively high risk of this procedure. HCT-CI was predictive of survival in the group of patients presented here, supporting previous reports in younger patients that comorbidities are likely a more important factor in determining potential benefit of transplant than age. Although it is not clear why our results differ from those of Andorsky et al., it is possible that it relates to either the very small sample size or lack of inclusion of higher-risk patients in the Andorsky report. In our small cohort, the HCT-CI was more sensitive than the CCI in capturing high-risk patients. In fact, 3 out of 4 (75%) patients who died within 100 days of transplant were identified http://www.selleckchem.com/products/cx-5461.html as high risk by the HCT-CI. This could be the basis for testing the validity of the HCT-CI in ASCT in elderly patients, and possibly across all age groups. Within this elderly population, http://www.selleckchem.com/products/forskolin.html when patients 75 and older were compared to those